Alzheimer’s Disease-models and Current Approaches: A Review
Abstract
Alzheimer's disease (AD) is a complicated CNS disorders that particularly affect the medial temporal lobe and neocortical area of the brain. AD is characterised by the progressive depletion of neurons in the cortical and hippocampal areas of the brain. The main symptoms are memory loss, amnesia, motor disturbance, mood change, and so on. Alzheimer's disease was 1.9% standard in the South Asian region in 2005; between 2020 and 2040, it's expected to reach an estimated 3.6M to 7.5M cases, respectively. Conversely, a pathological condition is characterized by alterations in microtubule stabilization and amyloid beta formation, resulting from increased oxidative stress and mitochondrial damage. Impairment of cerebral ROS formation is associated with brain mitochondrial dysfunction and deregulated signal transduction. The timely acquisition of relevant animal models for drug candidate screening represents a significant obstacle in neurological research and drug discovery. In this review, we have discussed various in vivo animal models which are helpful for neurological studies. In the end, the treatment for Alzheimer's Disease, modifying treatment strategies, is still under extensive research. We discussed various therapeutic targets to modify the treatment strategies and current drug treatment for AD.
Keywords:
Tau Protein, Animal Model, Alzheimer's Disease, Amyloid-β, ROSDOI
https://doi.org/10.25004/References
Breijyeh Z, Karaman R. Comprehensive review on Alzheimer’s disease: causes and treatment. Molecules. 2020 Dec 8;25(24):5789.
Ferri CP, Prince M, Brayne C, Brodaty H, Fratiglioni L, Ganguli M, Hall K, Hasegawa K, Hendrie H, Huang Y, Jorm A. Global prevalence of dementia: a Delphi consensus study. The lancet. 2005 Dec 17;366(9503):2112-7.
Ravindranath, V., Sundarakumar, J.S. Changing demography and the challenge of dementia in India. Nat Rev Neurol 2021; 17: 747–758.
Duggal P, Mehan S. Neuroprotective Approach of Anti-Cancer Microtubule Stabilizers Against Tauopathy Associated Dementia: Current Status of Clinical and Preclinical Findings. Journal of Alzheimer’s Disease Reports. 2019;3(1):179-218.
Perl DP. Neuropathology of Alzheimer's disease. Mount Sinai Journal of Medicine: A Journal of Translational and Personalized Medicine: A Journal of Translational and Personalized Medicine. 2010 Jan;77(1):32-42.
Kumar A, Sidhu J, Lui F, Tsao JW, Doerr C. Alzheimer Disease (Nursing). In: StatPearls. StatPearls Publishing, Treasure Island (FL); 2025.
Braak, H., Braak, E. Development of Alzheimer-related neurofibrillary changes in the neocortex inversely recapitulates cortical myelogenesis. Acta Neuropathol 1996; 92: 197–201.
Chin-Chan M, Navarro-Yepes J and Quintanilla-Vega B. Environmental pollutants as risk factors for neurodegenerative disorders: Alzheimer and Parkinson diseases. Front. Cell. Neurosci. 2015; 9:124.
Javanshiri K, Waldö ML, Friberg N, et al. Atherosclerosis, Hypertension, and Diabetes in Alzheimer’s Disease, Vascular Dementia, and Mixed Dementia: Prevalence and Presentation. Journal of Alzheimer’s Disease. 2018;65(4):1247-1258.
Santos CY. Cardiovascular and Retinal Vascular Changes in Preclinical Alzheimer's Disease. University of Rhode Island; 2018.
Kim J, Castellano JM, Jiang H, Basak JM, Parsadanian M, Pham V, Mason SM, Paul SM, Holtzman DM. Overexpression of low-density lipoprotein receptor in the brain markedly inhibits amyloid deposition and increases extracellular Aβ clearance. Neuron. 2009 Dec 10;64(5):632-44.
Munoz DG, Feldman H. Causes of Alzheimer's disease. Cmaj. 2000 Jan 11;162(1):65-72.
Swerdlow RH. Brain aging, Alzheimer's disease, and mitochondria. Biochimica et Biophysica Acta (BBA)-Molecular Basis of Disease. 2011 Dec 1;1812(12):1630-9.
Scheltens P, Blennow K, Breteler MM, De Strooper B, Frisoni GB, Salloway S, Van der Flier WM. Alzheimer's disease. The Lancet. 2016 Jul 30;388(10043):505-17
Murphy MP, LeVine H. Alzheimer’s Disease and the Amyloid-β Peptide. Journal of Alzheimer’s Disease. 2010;19(1):311-323. doi:10.3233/JAD-2010-1221
DeTure, M.A., Dickson, D.W. The neuropathological diagnosis of Alzheimer’s disease. Mol Neurodegeneration 2019; 14: 32.
Ashrafian H, Zadeh EH, Khan RH. Review on Alzheimer's disease: inhibition of amyloid beta and tau tangle formation. International journal of biological macromolecules. 2021 Jan 15; 167:382-94.
Salehi, A., Delcroix, JD. & Swaab, D. Alzheimer’s disease and NGF signaling. J Neural Transm 2004; 111: 323–345.
Thal DR, Rüb U, Orantes M, Braak H. Phases of Aβ-deposition in the human brain and its relevance for the development of AD. Neurology. 2002 Jun 25;58(12):1791-800.
Šimić G, Babić Leko M, Wray S, Harrington C, Delalle I, Jovanov-Milošević N, Bažadona D, Buée L, De Silva R, Di Giovanni G, Wischik C, Hof PR. Tau Protein Hyperphosphorylation and Aggregation in Alzheimer’s Disease and Other Tauopathies, and Possible Neuroprotective Strategies. Biomolecules, 2016; 6(1): 6.
Wegmann S, Biernat J, Mandelkow E. A current view on Tau protein phosphorylation in Alzheimer's disease. Current opinion in neurobiology. 2021 Aug 1;69:131-8.
Yu L, Chibnik LB, Yang J, McCabe C, Xu J, Schneider JA, De Jager PL, Bennett DA. Methylation profiles in peripheral blood CD4+ lymphocytes versus brain: The relation to Alzheimer's disease pathology. Alzheimer's & Dementia. 2016 Sep;12(9):942-51.
Noble W, Hanger DP, Miller CC, Lovestone S. The importance of tau phosphorylation for neurodegenerative diseases. Frontiers in neurology. 2013 Jul; 1:4:83.
Kocahan S, Doğan Z. Mechanisms of Alzheimer's Disease Pathogenesis and Prevention: The Brain, Neural Pathology, N-methyl-D-aspartate Receptors, Tau Protein and Other Risk Factors. Clinical psychopharmacology and neuroscience: the official scientific journal of the Korean College of Neuropsychopharmacology, 2017; 15(1): 1–8.
Congdon EE, Sigurdsson EM. Tau-targeting therapies for Alzheimer disease. Nat Rev Neurol 2018; 14: 399–415.
Pero RW, Roush GC, Markowitz MM, Miller DG. Oxidative stress, DNA repair, and cancer susceptibility. Cancer detection and prevention, 1990; 14(5): 555–561.
Jelinek M, Jurajda M, Duris K. Oxidative Stress in the Brain: Basic Concepts and Treatment Strategies in Stroke. Antioxidants, 2021; 10(12): 1886.
Ozkul A, Akyol A, Yenisey C, Arpaci E, Kiylioglu N, Tataroglu C. Oxidative stress in acute ischemic stroke. Journal of Clinical Neuroscience. 2007 Nov 1;14(11):1062-6.
Sayre LM, Perry G, Smith MA. Oxidative stress and neurotoxicity. Chemical research in toxicology. 2008 Jan 21;21(1):172-88.
Abd El Mohsen MM, Iravani MM, Spencer JP, Rose S, Fahim AT, Motawi TM, Ismail NA, Jenner P. Age-associated changes in protein oxidation and proteasome activities in rat brain: modulation by antioxidants. Biochemical and biophysical research communications. 2005 Oct 21;336(2):386-91.
Tsaluchidu S, Cocchi M, Tonello L, Puri BK. Fatty acids and oxidative stress in psychiatric disorders. BMC psychiatry. 2008 Apr 17;8(Suppl 1):S5.
Bennett S, Grant MM, Aldred S. Oxidative stress in vascular dementia and Alzheimer's disease: a common pathology. Journal of Alzheimer’s disease. 2008 Nov 10;17(2):245-57.
Pamplona R. Membrane phospholipids, lipoxidative damage and molecular integrity: a causal role in aging and longevity. Biochimica et Biophysica Acta (BBA)-Bioenergetics. 2008 Oct 1;1777(10):1249-62.
Chen JQ, Yager JD, Russo J. Regulation of mitochondrial respiratory chain structure and function by estrogens/estrogen receptors and potential physiological/pathophysiological implications. Biochimica et Biophysica Acta (BBA)-Molecular Cell Research. 2005 Oct 30;1746(1):1-7.
Ghezzi D, Zeviani M. Assembly Factors of Human Mitochondrial Respiratory Chain Complexes: Physiology and Pathophysiology. In: Kadenbach, B. (eds) Mitochondrial Oxidative Phosphorylation. Advances in Experimental Medicine and Biology, vol 748. Springer, New York, NY, 2012.
Della Bianca V, Dusi S, Bianchini E, Dal Prà I, Rossi F. β-Amyloid Activates the O⨪ 2 Forming NADPH Oxidase in Microglia, Monocytes, and Neutrophils: a possible inflammatory mechanism of neuronal damage in alzheimer's disease. Journal of Biological Chemistry. 1999 May 28;274(22):15493-9.
Blaikie L, Kay G, Maciel P, Lin PK. Experimental modelling of Alzheimer's disease for therapeutic screening. European Journal of Medicinal Chemistry Reports. 2022 Aug 1;5:100044.
Götz J, Ittner A, Ittner LM. Tau‐targeted treatment strategies in Alzheimer's disease. British journal of pharmacology. 2012 Mar;165(5):1246-59.
Ishihara T, Zhang B, Higuchi M, Yoshiyama Y, Trojanowski JQ, Lee VM. Age-dependent induction of congophilic neurofibrillary tau inclusions in tau transgenic mice. The American journal of pathology. 2001 Feb 1;158(2):555-62
Chen J, Kanai Y, Cowan NJ, Hirokawa N. Projection domains of MAP2 and tau determine spacings between microtubules in dendrites and axons. Nature. 1992 Dec 17;360(6405):674-7.
Hoshi M, Takashima A, Noguchi K, Murayama M, Sato M, Kondo S, Saitoh Y, Ishiguro K, Hoshino T, Imahori K. Regulation of mitochondrial pyruvate dehydrogenase activity by tau protein kinase I/glycogen synthase kinase 3beta in brain. Proceedings of the National Academy of Sciences. 1996 Apr 2;93(7):2719-23.
Kuo YM, Emmerling MR, Vigo-Pelfrey C, Kasunic TC, Kirkpatrick JB, Murdoch GH, Ball MJ, Roher AE. Water-soluble Aβ (N-40, N-42) Oligomers in Normal and Alzheimer Disease Brains (∗). Journal of Biological Chemistry. 1996 Feb 23;271(8):4077-81.
Davies P, Maloney AJ. Selective loss of central cholinergic neurons in Alzheimer's disease. Lancet (London, England), 1976; 2(8000), 1403.
Brem AK, Ran K, Pascual-Leone A. (2013). Learning and memory. Handbook of clinical neurology, 2013; 116, 693–737.
Wilcock GK, Esiri MM, Bowen DM, Smith CC. Alzheimer's disease. Correlation of cortical choline acetyltransferase activity with the severity of dementia and histological abnormalities. Journal of the neurological sciences, 1982; 57(2-3), 407–417.
Vannucci SJ. Developmental expression of GLUT1 and GLUT3 glucose transporters in rat brain. Journal of neurochemistry. 1994 Jan;62(1):240-6.
Vorbrodt A, Dobrogowska D, Tarnawski M. Immunogold study of interendothelial junction-associated and glucose transporter proteins during postnatal maturation of the mouse blood-brain barrier. J Neurocytol 2001; 30: 705–716.
Mann GE, Yudilevich DL, Sobrevia L. Regulation of amino acid and glucose transporters in endothelial and smooth muscle cells. Physiological reviews. 2003 Jan 1;83(1):183-252.
Ramsey KM, Mills KF, Satoh A, Imai SI. Age‐associated loss of Sirt1‐mediated enhancement of glucose‐stimulated insulin secretion in beta cell‐specific Sirt1‐overexpressing (BESTO) mice. Aging cell. 2008 Feb;7(1):78-88.
Burgering BM, Coffer PJ. Protein kinase B (c-Akt) in phosphatidylinositol-3-OH kinase signal transduction. Nature. 1995 Aug 17;376(6541):599-602.
Robey RB, Hay N. Is Akt the “Warburg kinase”?—Akt-energy metabolism interactions and oncogenesis. In Seminars in cancer biology. Academic Press. 2009 Feb 1; 19(1): 25-31.
Sun XJ, Crimmins DL, Myers MG, Miralpeix M, White MF. Pleiotropic Insulin Signals are Engaged by Multisite Phosphorylation of IRS-1. Molecular and Cellular Biology, 1993; 13(12): 7418–7428.
White MF. The insulin signalling system and the IRS proteins. Diabetologia. 1997 Jun;40(Suppl 2):S2-17.
Simpson RU, O'Connell TD, Pan Q, Newhouse J, Somerman MJ. Antisense oligonucleotides targeted against protein kinase Cβ and CβII block 1, 25-(OH) 2D3-induced differentiation. Journal of Biological Chemistry. 1998 Jul 31;273(31):19587-91.
Scali C, Prosperi C, Vannucchi MG, Pepeu G, Casamenti F. Brain inflammatory reaction in an animal model of neuronal degeneration and its modulation by an anti‐inflammatory drug: implication in Alzheimer's disease. European Journal of Neuroscience. 2000 Jun;12(6):1900-12.
Akiyama H, Barger S, Barnum S, Bradt B, Bauer J, Cole GM, Cooper NR, Eikelenboom P, Emmerling M, Fiebich BL, Finch CE. Inflammation and Alzheimer’s disease. Neurobiology of aging. 2000 May 1;21(3):383-421.
Moore AH, O'Banion MK. Neuroinflammation and anti-inflammatory therapy for Alzheimer's disease. Advanced drug delivery reviews, 2002; 54(12), 1627–1656.
Verkhratsky A, Olabarria M, Noristani HN, Yeh CY, Rodriguez JJ. Astrocytes in Alzheimer's disease. Neurotherapeutics. 2010 Oct 1;7(4):399-412.
Tuppo EE, Arias HR. The role of inflammation in Alzheimer's disease. The international journal of biochemistry & cell biology. 2005 Feb 1;37(2):289-305.
Dickson DW. Neuropathological diagnosis of Alzheimer’s disease: a perspective from longitudinal clinicopathological studies. Neurobiology of aging. 1997 Jul 1;18(4):S21-6.
Renauld AE, Spengler RN. Tumor necrosis factor expressed by primary hippocampal neurons and SH‐SY5Y cells is regulated by α2‐adrenergic receptor activation. Journal of neuroscience research. 2002 Jan 15;67(2):264-74.
Brand MD, Nicholls DG. Assessing mitochondrial dysfunction in cells. Biochemical journal. 2011 Apr 15;435(2):297-312.
Murphy MP. How mitochondria produce reactive oxygen species. Biochemical journal. 2009 Jan 1;417(1):1-3
Cassarino DS, Bennett Jr JP. An evaluation of the role of mitochondria in neurodegenerative diseases: mitochondrial mutations and oxidative pathology, protective nuclear responses, and cell death in neurodegeneration. Brain Research Reviews. 1999 Jan 1;29(1):1-25.
Pagani L, Eckert A. Amyloid-Beta interaction with mitochondria. International journal of Alzheimer's disease, 2011, 925050.
Gibson GE, Shi Q. A mitocentric view of Alzheimer's disease suggests multi-faceted treatments. Journal of Alzheimer’s disease. 2010 Jun 3;20(s2):S591-607.
Wang J, Xiong S, Xie C, Markesbery WR, Lovell MA. Increased oxidative damage in nuclear and mitochondrial DNA in Alzheimer's disease. Journal of neurochemistry. 2005 May;93(4):953-62.
Baloyannis SJ, Costa V, Michmizos D. Mitochondrial alterations Alzheimer's disease. American Journal of Alzheimer's Disease & Other Dementias®. 2004 Mar;19(2):89-93.
Manczak M, Anekonda TS, Henson E, Park BS, Quinn J, Reddy PH. Mitochondria are a direct site of Aβ accumulation in Alzheimer's disease neurons: implications for free radical generation and oxidative damage in disease progression. Human molecular genetics. 2006 May 1;15(9):1437-49.
Su B, Wang X, Nunomura A, Moreira PI, Lee HG, Perry G, Smith MA, Zhu X. Oxidative stress signaling in Alzheimer's disease. Current Alzheimer Research. 2008 Dec 1;5(6):525-32.
Devi L, Prabhu BM, Galati DF, Avadhani NG, Anandatheerthavarada HK. Accumulation of amyloid precursor protein in the mitochondrial import channels of human Alzheimer’s disease brain is associated with mitochondrial dysfunction. Journal of Neuroscience. 2006 Aug 30;26(35):9057-68.
Yao J, Rettberg JR, Klosinski LP, Cadenas E, Brinton RD. Shift in brain metabolism in late onset Alzheimer’s disease: implications for biomarkers and therapeutic interventions. Molecular aspects of medicine. 2011 Aug 1;32(4-6):247-57.
Lauterbach EC, Victoroff J, Coburn KL, Shillcutt SD, Doonan SM, Mendez MF. Psychopharmacological neuroprotection in neurodegenerative disease: assessing the preclinical data. The Journal of neuropsychiatry and clinical neurosciences. 2010 Jan;22(1):8-18.
Malik M, Fenko MD, Sheikh AM. et al. A Novel Approach for Characterization of Cathepsin D Protease and Its Effect on Tau and β-Amyloid Proteins. Neurochem Res 2011; 36: 754–760.
Obulesu M, Lakshmi MJ. Apoptosis in Alzheimer’s Disease: An Understanding of the Physiology, Pathology and Therapeutic Avenues. Neurochem Res 2014; 39: 2301–2312.
Rani V, Deshmukh R, Jaswal P, Kumar P, Bariwal J. Alzheimer's disease: Is this a brain specific diabetic condition?. Physiology & behavior. 2016 Oct 1;164:259-67.
Bhalla S, Mehan S, Khan A, Rehman MU. Protective role of IGF-1 and GLP-1 signaling activation in neurological dysfunctions. Neuroscience & Biobehavioral Reviews. 2022 Nov 1;142:104896.
Mehan S, Bhalla S, Siddiqui EM, Sharma N, Shandilya A, Khan A. Potential roles of glucagon-like peptide-1 and its analogues in dementia targeting impaired insulin secretion and neurodegeneration. Degenerative Neurological and Neuromuscular Disease. 2022 Mar; 7:31-59.
Erickson CA, Barnes CA. The neurobiology of memory changes in normal aging. Experimental gerontology. 2003 Jan 1;38(1-2):61-9.
Sherman KA, Friedman E. Pre‐and post‐synaptic cholinergic dysfunction in aged rodent brain regions: New findings and an interpretative review. International journal of developmental neuroscience. 1990;8(6):689-708.
Malekzadeh S, Edalatmanesh MA, Mehrabani D, Shariati M. Drugs Induced Alzheimer’s Disease in Animal Model:. Galen Med J [Internet]. 2017 Sep. 30; 6(3):e820.
Nakayama T, Sawada T. Involvement of microtubule integrity in memory impairment caused by colchicine. Pharmacology Biochemistry and Behavior. 2002 Jan 1;71(1-2):119-38.
Mukhtar E, Adhami VM, Mukhtar H. Targeting microtubules by natural agents for cancer therapy. Molecular cancer therapeutics. 2014 Feb 1;13(2):275-84.
Nazem A, Sankowski R, Bacher M, Al-Abed Y. Rodent models of neuroinflammation for Alzheimer’s disease. Journal of neuroinflammation. 2015 Apr 17;12(1):74.
More SV, Kumar H, Cho DY, Yun YS, Choi DK. Toxin-induced experimental models of learning and memory impairment. International journal of molecular sciences. 2016 Sep 1; 17(9):1447.
von Linstow Roloff E, Harbaran D, Micheau J, Platt B, Riedel G. Dissociation of cholinergic function in spatial and procedural learning in rats. Neuroscience. 2007 May 25;146(3):875-89.
Chen C, Li XH, Zhang S, Tu Y, Wang YM, Sun HT. 7, 8-dihydroxyflavone ameliorates scopolamine-induced Alzheimer-like pathologic dysfunction. Rejuvenation research. 2014 Jun 1;17(3):249-54.
Goverdhan P, Sravanthi A, Mamatha T. Neuroprotective effects of meloxicam and selegiline in scopolamine‐induced cognitive impairment and oxidative stress. International Journal of Alzheimer’s Disease. 2012; 2012(1):974013.
Schifilliti D, Santamaria LB, Rosa G, Di Nino G, Mandal PK, Fodale V. Cholinergic central system, Alzheimer's disease, and anesthetics liaison: a vicious circle?. Journal of Alzheimer’s Disease. 2010 Sep 29;22(s3):S35-41.
Li YS, Hong YF, He J, Lin JX, Shan YL, Fu DY, Chen ZP, Ren XR, Song ZH, Tao L. Effects of magnolol on impairment of learning and memory abilities induced by scopolamine in mice. Biological and Pharmaceutical Bulletin. 2013 May 1;36(5):764-71.
Riedel G, Kang SH, Choi DY, Platt B. Scopolamine-induced deficits in social memory in mice: reversal by donepezil. Behavioural brain research. 2009 Dec 1;204(1):217-25.
Lu P, Mamiya T, Lu LL, Mouri A, Zou LB, Nagai T, Hiramatsu M, Ikejima T, Nabeshima T. Silibinin prevents amyloid β peptide‐induced memory impairment and oxidative stress in mice. British journal of pharmacology. 2009 Aug;157(7):1270-7.
Desrumaux C, Pisoni A, Meunier J, Deckert V, Athias A, Perrier V, Villard V, Lagrost L, Verdier JM, Maurice T. Increased amyloid-β peptide-induced memory deficits in phospholipid transfer protein (PLTP) gene knockout mice. Neuropsychopharmacology. 2013 Apr;38(5):817-25.
Medina M, Avila J, Villanueva N. Use of okadaic acid to identify relevant phosphoepitopes in pathology: A focus on neurodegeneration. Marine Drugs. 2013 May 21;11(5):1656-68.
Liu M, Choi S, Cuny GD, Ding K, Dobson BC, Glicksman MA, Auerbach K, Stein RL. Kinetic studies of Cdk5/p25 kinase: phosphorylation of tau and complex inhibition by two prototype inhibitors. Biochemistry. 2008 Aug 12;47(32):8367-77.
Liu F, Grundke‐Iqbal I, Iqbal K, Gong CX. Contributions of protein phosphatases PP1, PP2A, PP2B and PP5 to the regulation of tau phosphorylation. European Journal of Neuroscience. 2005 Oct;22(8):1942-50. https://doi.org/10.1111/j.1460-9568.2005.04391.x
Zhang Z, Simpkins JW. An okadaic acid-induced model of tauopathy and cognitive deficiency. Brain research. 2010 Nov 4;1359:233-46.
Haidara MA, Mikhailidis DP, Rateb MA, Ahmed ZA, Yassin HZ, Ibrahim IM, Rashed LA. Evaluation of the effect of oxidative stress and vitamin E supplementation on renal function in rats with streptozotocin-induced Type 1 diabetes. Journal of Diabetes and its Complications. 2009 Mar 1;23(2):130-6.
Lester-Coll N, Rivera EJ, Soscia SJ, Doiron K, Wands JR, De la Monte SM. Intracerebral streptozotocin model of type 3 diabetes: relevance to sporadic Alzheimer's disease. Journal of Alzheimer’s disease. 2006 Apr 6;9(1):13-33. https://doi.org/10.3233/JAD-2006-9102
Mansouri MT, Naghizadeh B, Ghorbanzadeh B, Farbood Y, Sarkaki A, Bavarsad K. Gallic acid prevents memory deficits and oxidative stress induced by intracerebroventricular injection of streptozotocin in rats. Pharmacology biochemistry and behavior. 2013 Oct 1;111:90-6.
Khan MB, Khan MM, Khan A, Ahmed ME, Ishrat T, Tabassum R, Vaibhav K, Ahmad A, Islam F. Naringenin ameliorates Alzheimer’s disease (AD)-type neurodegeneration with cognitive impairment (AD-TNDCI) caused by the intracerebroventricular-streptozotocin in rat model. Neurochemistry international. 2012 Dec 1;61(7):1081-93.
Jellinger KA. The relevance of metals in the pathophysiology of neurodegeneration, pathological considerations. International review of neurobiology. 2013 Jan 1;110:1-47.
Jomova K, Valko M. Advances in metal-induced oxidative stress and human disease. Toxicology. 2011 May 10;283(2-3):65-87.
Bhattacharjee S, Zhao Y, Hill JM, Culicchia F, Kruck TP, Percy ME, Pogue AI, Walton JR, Lukiw WJ. Selective accumulation of aluminum in cerebral arteries in Alzheimer's disease (AD). Journal of Inorganic Biochemistry. 2013 Sep 1;126:35-7.
Haass C, Kaether C, Thinakaran G, Sisodia S. Trafficking and proteolytic processing of APP. Cold Spring Harbor perspectives in medicine. 2012 May 1;2(5):a006270.
Vassar R, Kandalepas PC. The β-secretase enzyme BACE1 as a therapeutic target for Alzheimer's disease. Alzheimer's research & therapy. 2011 May 31;3(3):20.
Chiang K, Koo EH. Emerging therapeutics for Alzheimer's disease. Annual review of pharmacology and toxicology. 2014 Jan 6;54(1):381-405.
P Imbimbo B, AM Giardina G. γ-secretase inhibitors and modulators for the treatment of Alzheimer's disease: disappointments and hopes. Current topics in medicinal chemistry. 2011 Jun 1;11(12):1555-70.
Wolfe MS. γ-Secretase as a target for Alzheimer’s disease. Advances in pharmacology. 2012 Jan 1;64:127-53.
Etcheberrigaray R, Tan M, Dewachter I, Kuipéri C, Van der Auwera I, Wera S, Qiao L, Bank B, Nelson TJ, Kozikowski AP, Van Leuven F. Therapeutic effects of PKC activators in Alzheimer's disease transgenic mice. Proceedings of the National Academy of Sciences. 2004 Jul 27;101(30):11141-6.
Vellas B, Sol O, J Snyder P, Ousset PJ, Haddad R, Maurin M, Lemarie JC, Desire L, P Pando M. EHT0202 in Alzheimer's disease: a 3-month, randomized, placebo-controlled, double-blind study. Current Alzheimer Research. 2011 Mar 1;8(2):203-12.
Holthoewer D, Endres K, Schuck F, Hiemke C, Schmitt U, Fahrenholz F. Acitretin, an enhancer of alpha-secretase expression, crosses the blood-brain barrier and is not eliminated by P-glycoprotein. Neurodegenerative diseases. 2012 Feb 1;10(1-4):224-8.
Knowles J. Donepezil in Alzheimer’s disease: an evidence-based review of its impact on clinical and economic outcomes. Core evidence. 2006 Mar 31;1(3):195-219.
Herrmann N, Li A, Lanctôt K. Memantine in dementia: a review of the current evidence. Expert opinion on pharmacotherapy. 2011 Apr 1;12(5):787-800.
Zhang B, Carroll J, Trojanowski JQ, Yao Y, Iba M, Potuzak JS, Hogan AM, Xie SX, Ballatore C, Smith AB, Lee VM. The microtubule-stabilizing agent, epothilone D, reduces axonal dysfunction, neurotoxicity, cognitive deficits, and Alzheimer-like pathology in an interventional study with aged tau transgenic mice. Journal of Neuroscience. 2012 Mar 14;32(11):3601-11.
Panza F, Solfrizzi V, Seripa D, Imbimbo BP, Lozupone M, Santamato A, Zecca C, Barulli MR, Bellomo A, Pilotto A, Daniele A. Tau‐Centric Targets and Drugs in Clinical Development for the Treatment of Alzheimer’s Disease. BioMed research international. 2016;2016(1):3245935.
Cai Z, Yan Y, Wang Y. Minocycline alleviates beta-amyloid protein and tau pathology via restraining neuroinflammation induced by diabetic metabolic disorder. Clinical interventions in aging. 2013 Aug 19:1089-95.
Pi R, Li W, Lee NT, Chan HH, Pu Y, Chan LN, Sucher NJ, Chang DC, Li M, Han Y. Minocycline prevents glutamate‐induced apoptosis of cerebellar granule neurons by differential regulation of p38 and Akt pathways. Journal of neurochemistry. 2004 Dec;91(5):1219-30.
Yu L, Wang W, Pang W, Xiao Z, Jiang Y, Hong Y. Dietary lycopene supplementation improves cognitive performances in tau transgenic mice expressing P301L mutation via inhibiting oxidative stress and tau hyperphosphorylation. Journal of Alzheimer’s Disease. 2017 Mar 21;57(2):475-82.
Vandenberghe R, Rinne JO, Boada M, Katayama S, Scheltens P, Vellas B, Tuchman M, Gass A, Fiebach JB, Hill D, Lobello K. Bapineuzumab for mild to moderate Alzheimer’s disease in two global, randomized, phase 3 trials. Alzheimer's research & therapy. 2016 May 12;8(1):18.
Doody RS, Thomas RG, Farlow M, Iwatsubo T, Vellas B, Joffe S, Kieburtz K, Raman R, Sun X, Aisen PS, Siemers E. Phase 3 trials of solanezumab for mild-to-moderate Alzheimer's disease. New England Journal of Medicine. 2014 Jan 23;370(4):311-21.
Perneczky R, Dom G, Chan A, Falkai P, Bassetti C. Anti‐amyloid antibody treatments for Alzheimer's disease. European journal of neurology. 2024 Feb;31(2):e16049.
Cummings J, Osse AM, Cammann D, Powell J, Chen J. Anti-amyloid monoclonal antibodies for the treatment of Alzheimer’s disease. BioDrugs. 2024 Jan;38(1):5-22.
Budd Haeberlein S, Aisen PS, Barkhof F, Chalkias S, Chen T, Cohen S, Dent G, Hansson O, Harrison K, von Hehn C, Iwatsubo T. Two randomized phase 3 studies of aducanumab in early Alzheimer’s disease. The journal of prevention of Alzheimer's disease. 2022 Apr;9(2):197-210.
Swanson CJ, Zhang Y, Dhadda S, Wang J, Kaplow J, Lai RY, Lannfelt L, Bradley H, Rabe M, Koyama A, Reyderman L. A randomized, double-blind, phase 2b proof-of-concept clinical trial in early Alzheimer’s disease with lecanemab, an anti-Aβ protofibril antibody. Alzheimer's research & therapy. 2021 Apr 17;13(1):80.
Mintun MA, Lo AC, Duggan Evans C, Wessels AM, Ardayfio PA, Andersen SW, Shcherbinin S, Sparks J, Sims JR, Brys M, Apostolova LG. Donanemab in early Alzheimer’s disease. New England Journal of Medicine. 2021 May 6;384(18):1691-704.
Published
Abstract Display: 0 How to Cite
Issue
Section
Copyright (c) 2026 Mayank Sharma, Nandini Sharma, Aayush Sharma, Ajit Kiran Kaur
This work is licensed under a Creative Commons Attribution 4.0 International License.
